Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 39 citing articles:

Recent advances and evolving concepts in Still’s disease
Piero Ruscitti, Luca Cantarini, Peter A. Nigrović, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 2, pp. 116-132
Closed Access | Times Cited: 30
Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts
Helen L. Leavis, Paul Van Daele, Catharina M. Mulders‐Manders, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 6, pp. 1656-1663
Open Access | Times Cited: 24
Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
Sara Bindoli, Chiara Baggio, Andrea Doria, et al.
Drugs (2024) Vol. 84, Iss. 3, pp. 257-274
Open Access | Times Cited: 9
The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature
Roberto Giacomelli, Jurgen Sota, Piero Ruscitti, et al.
Clinical and Experimental Rheumatology (2021) Vol. 39, Iss. 1, pp. 187-195
Open Access | Times Cited: 47
Efficacy and safety of therapies for Still’s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still’s disease
Sara Bindoli, Arianna De Matteis, Stéphane Mitrovic, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-225854
Closed Access | Times Cited: 7
Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients
Piero Ruscitti, Onorina Berardicurti, Daniela Iacono, et al.
Arthritis Research & Therapy (2020) Vol. 22, Iss. 1
Open Access | Times Cited: 44
Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still’s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort
Paola Di Benedetto, Paola Cipriani, Daniela Iacono, et al.
PLoS ONE (2020) Vol. 15, Iss. 7, pp. e0235326-e0235326
Open Access | Times Cited: 43
Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus
Piero Ruscitti, Yannick Allanore, Chiara Baldini, et al.
Autoimmunity Reviews (2024) Vol. 23, Iss. 7-8, pp. 103581-103581
Closed Access | Times Cited: 5
The Systemic Score May Identify Life‐Threatening Evolution in Still Disease: Data from the GIRRCS AOSD‐Study Group and the AIDA Network Still Disease Registry
Piero Ruscitti, Francesco Masedu, Antonio Vitale, et al.
Arthritis & Rheumatology (2024) Vol. 76, Iss. 7, pp. 1141-1152
Closed Access | Times Cited: 4
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission
Roberto Giacomelli, Roberto Caporali, Francesco Ciccia, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 12, pp. 103400-103400
Closed Access | Times Cited: 9
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry
Piero Ruscitti, Francesco Masedu, Antonio Vitale, et al.
RMD Open (2023) Vol. 9, Iss. 4, pp. e003419-e003419
Open Access | Times Cited: 9
Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort
Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli, et al.
Rheumatology International (2019) Vol. 40, Iss. 1, pp. 107-113
Closed Access | Times Cited: 24
The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still’s disease. A systematic review and meta-analysis of observational studies
Piero Ruscitti, Francesco Ursini, Jurgen Sota, et al.
Therapeutic Advances in Musculoskeletal Disease (2020) Vol. 12
Open Access | Times Cited: 21
DGRh-S2e-Leitlinie
Stefan Vordenbäumen, Eugen Feist, Jürgen Rech, et al.
Zeitschrift für Rheumatologie (2022) Vol. 81, Iss. S1, pp. 1-20
Open Access | Times Cited: 13
Clinical phenotypes and prognostic factors of adult-onset Still’s disease: data from a large inpatient cohort
Rui Li, Xiaolei Liu, Guangliang Chen, et al.
Arthritis Research & Therapy (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 16
Clinical characteristics of obese patients with adult-onset Still's disease. Data from a large multicentre cohort
Ilenia Di Cola, Daniela Iacono, Ilenia Pantano, et al.
Joint Bone Spine (2023) Vol. 90, Iss. 5, pp. 105576-105576
Open Access | Times Cited: 7
The latest advances in the use of biological DMARDs to treat Still’s disease
Ilenia Di Cola, Piero Ruscitti
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 1-2, pp. 63-75
Closed Access | Times Cited: 2
Adult-onset Still's disease with elderly onset, results from a multicentre study
Ilenia Di Cola, Claudia Di Muzio, Alessandro Conforti, et al.
Clinical and Experimental Rheumatology (2021)
Open Access | Times Cited: 16
The clinical heterogeneity of adult onset Still’s disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients
Piero Ruscitti, Onorina Berardicurti, Roberto Giacomelli, et al.
Seminars in Immunology (2021) Vol. 58, pp. 101632-101632
Closed Access | Times Cited: 15
Clinical characteristics and outcome of elderly onset adult-onset Still's disease: A 10-year retrospective study
Sheng Li, Shuni Ying, Juan Bai, et al.
Journal of Translational Autoimmunity (2023) Vol. 6, pp. 100196-100196
Open Access | Times Cited: 5
Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease
Antonio Vitale, Valeria Caggiano, Petros P. Sfikakis, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 4
Implementation of the new DGRh S2e guideline on diagnostics and treatment of adult-onset Still’s disease in Germany
R Friedrich, Anna Kernder, Norbert Blank, et al.
Zeitschrift für Rheumatologie (2024)
Closed Access | Times Cited: 1
Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guideline
Stefan Vordenbäumen, Eugen Feist, Jürgen Rech, et al.
Zeitschrift für Rheumatologie (2022) Vol. 82, Iss. S2, pp. 81-92
Open Access | Times Cited: 6
Efficacy and safety of 5-aminolevulinic acid in adult-onset Still's disease: A preclinical study in mice and a pilot study in humans
Tomohiro Koga, Remi Sumiyoshi, Yoshika Tsuji, et al.
Clinical Immunology (2023) Vol. 257, pp. 109846-109846
Open Access | Times Cited: 3
<p>Schnitzler Syndrome in a 27-Year-Old Man: Diagnostic and Therapeutic Dilemma in Adult Auto-Inflammatory Syndromes A Case Report and Literature Review</p>
Ewa Więsik‐Szewczyk, Anna Felis-Giemza, Mirosław Dziuk, et al.
International Journal of General Medicine (2020) Vol. Volume 13, pp. 713-719
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top